Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Gossamer Bio Inc GOSS

Healthcare Biotechnology
Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH). Its product candidate Seralutinib, also known as GB002, is an investigational inhaled, small molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor... see more

Recent & Breaking News (NDAQ:GOSS)

Gossamer Bio Announces Appointment of Bryan Giraudo as Chief Operating Officer, in addition to Chief Financial Officer Role

Business Wire September 21, 2021

Gossamer Bio Announces Second Quarter 2021 Financial Results and Provides Corporate Update

Business Wire August 9, 2021

Gossamer Bio to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 9, 2021

Business Wire August 2, 2021

Gossamer Bio Announces GB004 Clinical Trial Data Presentations at 2021 Virtual Congress of the European Crohn's and Colitis Organisation

Business Wire July 7, 2021

Gossamer Bio Announces Promotion of Richard Aranda, M.D., to Chief Medical Officer

Business Wire June 21, 2021

Gossamer Bio Announces Appointment of Sandra Milligan, M.D., J.D., to its Board of Directors

Business Wire June 14, 2021

Gossamer Bio Announces First Quarter 2021 Financial Results and Provides Corporate Update

Business Wire May 6, 2021

Gossamer Bio Announces Executive Management Transition and Promotion of Laura Carter, Ph.D., to Chief Scientific Officer

Business Wire April 20, 2021

Gossamer Bio Announces Promotion of Caryn Peterson to Executive Vice President, Regulatory Affairs

Business Wire April 16, 2021

Gossamer Bio Announces Fourth Quarter and Full-Year 2020 Financial Results and Provides Business Update

Business Wire February 25, 2021

Gossamer Bio to Announce Fourth Quarter and Full-Year 2020 Financial Results and Host Conference Call and Webcast on February 25, 2021

Business Wire February 19, 2021

Gossamer Bio to Host Webcast Focused on its Inflammatory Bowel Disease Program, GB004, on February 18, 2021

Business Wire February 4, 2021

Aerpio Announces Statistically Significant Topline Results from Razuprotafib Glaucoma Phase 2 Trial

GlobeNewswire December 11, 2020

Gossamer Bio to Host Webcast Focused on GB002 and Pulmonary Arterial Hypertension (PAH) on December 15, 2020

Business Wire December 7, 2020

Gossamer Bio Announces Appointment of Faheem Hasnain as Chief Executive Officer

Business Wire November 16, 2020

Gossamer Bio Announces Third Quarter 2020 Financial Results and Provides Corporate Update

Business Wire November 10, 2020

Aerpio Reports Third Quarter 2020 Financial Results and Provides Business Update

GlobeNewswire November 10, 2020

Gossamer Bio to Announce Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 10, 2020

Business Wire November 6, 2020

Gossamer Bio Announces GB1275 Data Presentations at 2020 Society for Immunotherapy of Cancer Annual Meeting

Business Wire November 6, 2020

Gossamer Bio Announces Topline Results for Phase 2 Trials of Oral GB001 in Asthma and Chronic Rhinosinusitis

Business Wire October 13, 2020